Domvanalimab clinical trials
Also written AB154 and GS-0154.
How each study uses domvanalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the domvanalimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 3 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 9
Gilead Sciences (5) · Arcus Biosciences, Inc. (4) · Hospices Civils de Lyon (2) · Washington University School of Medicine (1) · Fundación para el Progreso de la Oncología en Cantabria (1) · AstraZeneca (1) · University of Texas Southwestern Medical Center (1) · Yale University (1)
Often tested with
Tested in the same studies.
Zimberelimab (14) · Sacituzumab govitecan (3) · AB928 (2) · Quemliclustat (2) · FOLFOX-4 Regimen (1) · Platinum Doublet (1) · Carboplatin (1) · Pemetrexed (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test domvanalimab.
- Mar 2027Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01Phase 2 · Gilead Sciences
- Apr 2027Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerPhase 2 · Washington University School of Medicine
Studies
Open first, then newest update. How each study uses domvanalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)Not yet recruitingPhase 2Hospices Civils de LyonNCT07337447Written as FOLFIRI + Zimberelimab + Domvanalimab
- Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerActive, not recruitingPhase 2Washington University School of MedicineNCT04791839Written as Domvanalimab
- A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesCompletedPhase 2Arcus Biosciences, Inc.NCT05329766Written as Domvanalimab
- Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerCompletedPhase 2Arcus Biosciences, Inc.NCT04736173Written as Domvanalimab
- PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder CancerActive, not recruitingPhase 2Fundación para el Progreso de la Oncología en CantabriaNCT06133517Written as Domvanalimab
- Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01Active, not recruitingPhase 2Gilead SciencesNCT06727565Written as Domvanalimab
- A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the BodyCompletedPhase 3Arcus Biosciences, Inc.NCT05568095Written as Domvanalimab
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingPhase 2Gilead SciencesNCT03547973Written as Domvanalimab
- A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCActive, not recruitingPhase 3AstraZenecaNCT05211895Written as Domvanalimab
- Domvanalimab and Zimberelimab in Advanced Liver CancersActive, not recruitingPhase 2University of Texas Southwestern Medical CenterNCT05724563Written as Domvanalimab
- IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersActive, not recruitingPhase 2Hospices Civils de LyonNCT06790706Written as DOMVANALIMAB + ZIMBERELIMAB
- Study With Various Immunotherapy Treatments in Participants With Lung CancerActive, not recruitingPhase 2Gilead SciencesNCT05676931Written as Domvanalimab
- Study of Novel Treatment Combinations in Patients With Lung CancerActive, not recruitingPhase 2Gilead SciencesNCT05633667Written as Domvanalimab (DOM)
- Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBCWithdrawnPhase 2MedSIRNCT07134556Written as Domvanalimab (DOM)
- AB154 Combined With AB122 for Recurrent GlioblastomaActive, not recruitingEarly Phase 1Yale UniversityNCT04656535Written as Domvanalimab
- Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory MelanomaActive, not recruitingPhase 2Diwakar DavarNCT05130177Written as Domvanalimab
- Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerActive, not recruitingPhase 3Gilead SciencesNCT05502237Written as Domvanalimab
- Zimberelimab + Domvanalimab in Gastroesophageal AdenocarcinomaWithdrawnPhase 2Massachusetts General HospitalNCT07283848Written as Domvanalimab
- A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced MalignanciesCompletedPhase 1Arcus Biosciences, Inc.NCT03628677Written as Domvanalimab
Given beside what is tested · 3 — domvanalimab is usual care or a partner of the new treatment
- AB122 Platform StudyRecruitingPhase 1Taiho Pharmaceutical Co., Ltd.NCT04999761Written as AB154
- Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung CancerCompletedPhase 2Arcus Biosciences, Inc.NCT04262856Written as Domvanalimab
- Switch Maintenance in PancreaticSuspendedPhase 1/2James Cleary, MD, PhDNCT05419479Written as DOMVANALIMAB
Codes
What other systems call domvanalimab · ClinicalTrials.gg INT014805
- UNII (FDA) 45X7OU8C4JDOMVANALIMABOne source FDA
- NCI Thesaurus C162875DomvanalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 45X7OU8C4J | DOMVANALIMAB | One source FDA |
| NCI Thesaurus | C162875 | Domvanalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.